Neuronetics, Inc. Announces Grand Opening of NeuroStar® University with Ribbon-Cutting Ceremony
September 13, 2022 08:33 ET
|
Neuronetics
MALVERN, Pa., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces 510(k) Clearance of D-Tect™ MT Accessory for NeuroStar® Advanced Therapy for Mental Health
August 29, 2022 08:30 ET
|
Neuronetics
MALVERN, Pa., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics and Alleviant Health Centers Announce Exclusive Partnership
July 25, 2022 08:31 ET
|
Neuronetics
Partnership Will Bring Non-drug NeuroStar® Advanced Therapy for Mental Health to Thousands More Patients MALVERN, Pa., July 25, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Anxious Depression
July 19, 2022 07:00 ET
|
Neuronetics
MALVERN, Pa., July 19, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Recognized as Top Non-Invasive Devices Provider in 2022
July 13, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., July 13, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
Neuronetics Announces Positive TMS Coverage Policies to Expand Patient Access to NeuroStar TMS Therapy for Mental Health
July 11, 2022 16:46 ET
|
Neuronetics
MALVERN, Pa., July 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever...
New Peer-Reviewed Data Continue to Further Best Practices with NeuroStar® Advanced Therapy
May 17, 2022 08:31 ET
|
Neuronetics
Published in Brain Stimulation Journal, study describes insights from world’s largest depression registry MALVERN, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a...
Neuronetics TMS Leadership on Display at Clinical TMS Society Annual Meeting
May 11, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., May 11, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar® Advanced Therapy for Mental Health Receives FDA Clearance for Treatment of Obsessive-Compulsive Disorder
May 10, 2022 08:31 ET
|
Neuronetics
MALVERN, Pa., May 10, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve...
NeuroStar Advanced Therapy for Mental Health Announces Partnership with Mental Health Advocate and Former Major League Baseball Player Drew Robinson
May 03, 2022 12:59 ET
|
Neuronetics
A Media Snippet accompanying this announcement is available by clicking on the image or link below: MALVERN, Pa., May 03, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial...